Background. We report composite results from the Merck phase I program of near-consensus clade B human immunodeficiency virus (HIV) type 1 gag vaccines.
Even with significant advances in therapy, the AIDS pandemic continues to be responsible for devastating morbidity and mortality throughout the world [1] [2] [3] [4] , especially in regions with limited access to antiretroviral medications. Human immunodeficiency virus (HIV) vaccine strategies to elicit protection by neutralizing antibodies have met with repeated failures [5] [6] [7] . Di-ies, the Merck adenovirus type 5 (Ad5)-vectored near-consensus clade B HIV-1 vaccines were immunogenic in HIV-seronegative subjects [16] [17] [18] . Disappointingly, the STEP proof-ofconcept trial failed to demonstrate benefit from a 3-dose regimen of a trivalent Ad5 vaccine, and numerically more HIV infections were acquired by vaccine recipients than by placebo recipients in some subgroups [19, 20] . Despite the unexpected results of the STEP study, it remains imperative to explore all aspects of the Merck HIV vaccine program to inform future vaccine efforts against HIV and other intracellular pathogens [20, 21] .
Development of an effective CMI-based vaccine regimen against HIV must address several challenges [20] [21] [22] . The STEP trial results underscored the need to better understand the role of immunodominance and antigenic breadth in vaccine development. Both quantitative and qualitative aspects of effective CMI responses to natural infection and vaccines are still not sufficiently understood. Vaccines using viral vectors such as Ad5 can elicit robust immune responses to transgene inserts [16-19, 23, 24] . However, for vectors derived from common human viral pathogens, neutralizing antibodies from natural infection may attenuate or otherwise negatively affect vaccine immunogenicity [25] . Preexistent and/or vaccine-induced immunity to the Ad5 vector substantially dampens the CMI response to Ad5-vectored HIV-1 vaccines [16, 17] . One strategy to overcome high Ad5 titers would be to use a DNA vaccine for the entire series or as a priming series before a booster dose of an Ad5 vaccine [26] . Furthermore, the use of adjuvants may significantly enhance immune responses to some DNA vaccines [27] [28] [29] [30] .
In a nonhuman primate model, the combination of DNA priming and Ad5 boosting resulted in better short-term control of simian immunodeficiency virus compared with a regimen consisting of Ad5-vaccine alone [26] , indicating that a DNA-prime Ad5-boost vaccine regimen could enhance immune responses at least transiently. Nonetheless, single-vaccine regimens have significant logistical advantages with regard to manufacturing, distribution, and implementation of immunization programs. A clear benefit would need to be reasonably anticipated for a prime-boost regimen using 2 different vaccines to be a preferred option.
We have conducted 6 independent phase I studies of a HIV-1 gag vaccine administered as follows: (1) priming and boosting with the DNA vaccine (DNA/DNA regimen), (2) priming with DNA vaccine and boosting with the Ad5 vaccine (DNA/Ad5 regimen), and (3) priming and boosting with the Ad5 vaccine (Ad5/Ad5 regimen). The effects of these different regimens on enzyme-linked immunospot (ELISpot) responses to HIV-1 clade B Gag peptide pools measured 4 weeks after the last dose are the major focus of our analysis.
MATERIALS AND METHODS

Objectives and outcomes.
The primary objective of the 6 studies (Merck V520 protocols 002, 007, 008, 011, 012, and 018) was to assess the safety, tolerability, and immunogenicity of various delivery strategies for a near-consensus clade B HIV-1 gag vaccine. Results from protocols 007, 012, and 018 have been reported elsewhere [17, 18] . Protocol 002 evaluated a regimen of repeated vaccinations with gag DNA vaccine in phosphate-buffered saline (PBS) at 1 or 5 mg per dose. Protocol 008 evaluated a priming series of the gag DNA vaccine at the 5-mg dosage with or without aluminum phosphate (AlPO 4 ) adjuvant, followed by a boosting dose with the same DNA vaccine or the Ad5 vaccine containing viral particles (vp). Pro- 10 1 ϫ 10 tocol 011 evaluated a priming series of the gag DNA vaccine at the 5-mg dose, containing either the AlPO 4 or CRL1005 adjuvant, followed by a boosting dose with the same DNA vaccine or the Ad5 vaccine containing or vp. 8 1 0
1 ϫ 10 1 ϫ 10 The aim of the current analysis was to assess the effects on the immune response of the following 3 strategies: (1) a 4-dose regimen of a DNA gag vaccine alone, containing 5 mg per 1-mL dose; (2) a 3-dose priming regimen of the DNA gag vaccine (5 mg/dose), followed by a booster dose of an Ad5 gag vaccine at vp per 1-mL dose; and (3) a 3-dose regimen of an 10 1 ϫ 10 Ad5 gag vaccine ( vp/dose). Depending on the study, 10 1 ϫ 10 the DNA vaccine was provided in PBS with or without an AlPO 4 or CRL1005 adjuvant. Immunogenicity end points were the proportions of subjects with a positive unfractionated gag-specific interferon (IFN) g ELISpot response to 15-mer Gag peptide pools using peripheral blood mononuclear cells (PBMCs) obtained periodically after vaccination, including 4 weeks after the last priming dose (week 12 for DNA-based regimens and week 8 for the Ad5/Ad5 regimen) and 4 weeks after the final dose (week 30 for all regimens).
Vaccine compositions. Three DNA vaccine formulations were studied. Each of the DNA formulations contained the HIV-1 gag plasmid expressing the gag gene from an HIV-1 strain (CAM-1) that closely resembles the clade B consensus amino acid sequence. The vaccine backbone comprises a cytomegalovirus promoter and intron A, a bovine growth hormone-derived polyadenylation and transcriptional termination sequence, and is derived from a pUC backbone. The plasmid is propagated in Escherichia coli and then isolated using a chromatography-based process. The gag transgene is expressed to high levels in mammalian cells, whereas the plasmid replicates only in E. coli.
The HIV-1 gag DNA plasmid was formulated in a sterile solution of PBS (6 mmol/L sodium phosphate, 150 mmol/L sodium chloride; pH 7.2) with or without either AlPO 4 adjuvant (0.7 mg/mL) or the nonionic block copolymer adjuvant CRL1005 (7.5 mg/mL) with 0.6 mmol/L benzalkonium chloride. CRL1005 (CytRx) is a linear triblock copolymer with a polyoxypropylene core of molecular weight 12 kDa and 5% polyoxyetheylene [29, 30] . Placebo consisted of an identical PBS solution, with or without 0.7 mg of AlPO 4 per milliliter.
Two similar adenoviral vectors (Ad5 HIV-1 gag and MRKAd5 HIV-1 gag) were studied, both based on a replication-defective adenovirus type 5 backbone [14, [16] [17] [18] . The immunogenicity and safety profiles of these vectors were similar, but the original Ad5 vector exhibited more genetic instability with passage than did MRKAd5.
Study designs. All studies in this analysis were multicenter, blinded, randomized, placebo-controlled phase I trials ( Figure  1 ). Healthy subjects between 18 and 55 years of age without evidence of HIV infection were assessed for eligibility. Subjects were excluded if they were considered to be at high risk of acquiring HIV infection during the study or had a history of significant chronic medical conditions. Female subjects with childbearing potential were required to have a negative urine pregnancy test immediately before receiving any injections. Protocols were approved by the institutional review boards at participating centers. Written informed consent was obtained from all subjects. Within each study, enrolled subjects were randomized to receive vaccine or placebo according to allocation schedules generated by computer. Ad5 neutralizing antibody titers were measured at baseline in all studies, and these titers were used to stratify enrollment in some protocols. Investigators, subjects, clinical safety monitors, and laboratory personnel performing the biological assays were blinded to treatment assignments. Clinic visits for safety evaluations were scheduled for 2-4 weeks after each dose. Study personnel monitored injection site, systemic, and laboratory adverse events. All studies except protocol 018 were conducted exclusively in the United States. Although protocol 018 was conducted internationally, only data from subjects enrolled at sites in the United States were included, to avoid confounding due to genetic heterogeneity among subjects and different PBMC-processing protocols across the world regions [18] .
Laboratory assays. Neutralizing antibodies to Ad5 were measured as described elsewhere; a titer of !18 was considered negative, as defined by the assay specifications [31] . As in earlier analyses, a cutoff titer of 200 was used to categorize high versus low baseline immunity to Ad5 [16] [17] [18] [19] .
To assess vaccine immunogenicity, unfractionated IFN-g ELISpot assays using 15-mer clade B HIV-1 Gag peptide pools matched to the vaccine inserts were performed on PBMCs obtained at weeks 4, 8, 12, 26, 30, 34 , and 42 at Merck Research Laboratories to detect HIV-1 gag-specific T cell responses after vaccination [32] . A positive ELISpot response was defined as у55 spot-forming cells (SFCs)/10 6 PBMCs and у4-fold increased response compared with the control medium. The relative contribution of CD4 and CD8 T cells to the IFN-g response was assessed by intracellular cytokine flow cytometry [33] ; a positive response was defined as у400 CD4 + or CD8 + IFN-g positive events/10 6 lymphocytes and у3-fold increased response compared with the control medium. Statistical analyses. Data were combined across protocols. Cell processing and immunological assays for all specimens used in this analysis were conducted, using standardized procedures that ensured the comparability of results across studies. Because the Ad5 and MRKAd5 vaccine vectors had produced observationally similar ELISpot responses, the analyses in this report combined these 2 vectors in the Ad5 vaccine groups [16] . Because a dose response was apparent for both the DNA and Ad5 vaccines, analysis was limited to the 5-mg dose group for the DNA vaccine and to the -vp dose group for the 10 1 ϫ 10 Ad5 vaccine.
Only subjects receiving all scheduled doses of vaccine and without major protocol violations were included in the analysis of immunogenicity. Results of unfractionated HIV-1 gag-specific IFN-g ELISpot assays were summarized according to vaccine regimen at each time point. Summary statistics included the proportions of ELISpot responders and the geometric means of the quantitative ELISpot values for each treatment group. Geometric means were calculated for all subjects, regardless of whether their ELISpot result was deemed positive or negative. Summary data are also presented separately for subjects with high (1200) or low (р200) baseline Ad5 titers. Between-group differences in the frequencies of ELISpot responders were evaluated using the method of Miettinen and Nurminen [34] . The key pairwise comparisons of interest were the unadjuvanted DNA vaccine versus either the AlPO 4 -or CRL1005-adjuvanted DNA vaccine and the Ad5/Ad5 regimen versus either the DNA/DNA or the DNA/Ad5 regimen. Dunnett's multiplicity adjustment [35] was applied separately for the 2 sets of comparisons, and differences were considered statistically significant at (2-tailed multiplicity-adjusted P ! .05 P values). An analogous testing approach using pairwise t tests was used to compare geometric mean unfractionated ELISpot responses as well as geometric mean CD4 + and CD8 + T cell responses determined by intracellular cytokine flow cytometry. 
RESULTS
Subject accounting and baseline characteristics.
The demographic characteristics across the vaccine groups were generally comparable (Table 1) . Of 307 randomized subjects eligible for this analysis, 254 (83%) completed the studies through week 30 and were included in the primary immunogenicity analysis. Subjects in protocol 002 received a second booster dose of vaccine у6 months after the first booster dose, and many subjects in protocols 007 and 012 were rolled over into another vaccine trial [36] . Accordingly, the current analysis includes only data up to the week 42 visit in all studies.
Immunogenicity. Table 2 shows descriptive summaries of the postpriming and postboosting ELISpot results for the 7 vaccine regimens in subjects in the per-protocol population. The response frequency and magnitude differed by regimen.
Unadjuvanted versus adjuvanted DNA vaccine regimens. The addition of an adjuvant did not appear to enhance the priming response to the DNA vaccines. Compared with the DNA vaccine without an adjuvant, neither AlPO 4 nor CRL1005 significantly augmented the ELISpot responses to the priming regimen at week 12. The priming series was identical for regimens 1 and 4, regimens 2 and 5, and regimens 3 and 6 listed in Table 2 , allowing us to combine the DNA regimens that used the same adjuvant for the analysis at week 12. The percentages of responders assessed 4 weeks after completion of the priming series (week 12) were 21.9% (geometric mean ELISpot response, 67) for the PBS diluent without an adjuvant (regimens 1 + 4; ), compared with 22.5% (ELISpot response, 79) n p 64 and 16.0% (ELISpot response, 70) for PBS with AlPO 4 (regimens 2 + 5;
) or CRL1005 (regimens 3 + 6; ), n p 71 n p 50 respectively. The postprime response frequency for all the DNA groups combined (regimens 1-6; ) was 20.5% (geon p 185 metric mean ELISpot response, 72). Furthermore, there was no statistical evidence to suggest that the addition of AlPO 4 or CRL1005 to the DNA vaccine formulation affected the ELISpot responses when subjects were later given booster doses with either the DNA or Ad5 vaccine. Although the DNA vaccine with the CRL1005 adjuvant yielded the numerically lowest response rates, these results were not significantly inferior to those of the DNA vaccine without an adjuvant. Consequently, results were pooled across the DNA formulations irrespective of adjuvant, in order to compare vaccine regimens.
Ad5/Ad5 versus DNA/DNA or DNA/Ad5 regimens. Statistically significant differences in the proportion of ELISpot responders and corresponding geometric means were detected between the DNA/DNA and Ad5/Ad5 regimens but not between the DNA/Ad5 and Ad5/Ad5 regimens assessed 4 weeks after the booster dose at week 30 (Table 3) . After empirical exclusion of subjects receiving the DNA vaccine with the CRL1005 adjuvant (which consistently yielded the lowest ELISpot responses) and pooling of the 2 other DNA-prime (with PBS ‫ע‬ AlPO 4 ) Ad5-boost arms, a modestly higher postboost response frequency of 62% was achieved, compared with the 50% postboost response after the Ad5/Ad5 regimen.
Baseline Ad5 titer effect. Not unexpectedly, baseline Ad5 titers did not consistently affect DNA vaccine responses. On the other hand, the immunogenicity of the Ad5 vaccine was systematically affected by baseline Ad5 titers. The time course of ELISpot responses for DNA/DNA, DNA/Ad5, and Ad5/Ad5 vaccine regimens are displayed in Figure 2 by Ad5 status. For the Ad5/Ad5 regimen, subjects in the lower Ad5 titer group had notably higher postprime and postboost responses than 6 peripheral blood mononuclear cells (PBMCs) and у4-fold higher than the control medium. Geometric mean ELISpot responses are reported as SFCs/10 6 PBMCs, and include both responders and nonresponders. Numbers under graphs (N) represent all subjects with available data who had completed the vaccine series to the specified time point. subjects in the higher Ad5 titer group (Table 2 ). In the lower Ad5 titer group, statistically significant differences in the proportion of ELISpot responders and corresponding geometric means were detected between the Ad5/Ad5 and DNA/DNA (but not between the Ad5/Ad5 and DNA/Ad5) regimens; however, no significant differences were detected between vaccine regimens in the higher Ad5 titer group (Table 3) . Overall, the DNAprime Ad5-boost strategy did not materially increase the ELISpot responses relative to the Ad5/Ad5 regimen in the group with high baseline Ad5 titers. After subjects receiving the CRL1005-adjuvanted DNA vaccine were empirically excluded from that group, the corresponding week 30 ELISpot response frequencies were 37% with the DNA-prime (with PBS 3 AlPO 4 ) Ad5-boost regimen versus 24% with the Ad5/Ad5 regimen.
Qualitative T cell responses. The DNA/DNA vaccine regimen generated a primarily CD4 + T cell response, whereas the Ad5/Ad5 vaccine regimen induced a predominant CD8 + T cell response ( Table 4 ). The DNA/Ad5 regimen produced a CD4 + T cell response comparable to that of the DNA/DNA regimen and a CD8 + T cell response comparable to that of the Ad5/ Ad5 regimen.
DISCUSSION
In this analysis of near-consensus clade B HIV-1 gag vaccines, we did not demonstrate a clear benefit of a DNA vaccine over an Ad5-only regimen in enhancing CMI responses, as measured by unfractionated IFN-g ELISpot responses. In particular, DNA priming did not appear to overcome the dampening of immune responses to the Ad5 vaccine in subjects with preexisting Ad5 neutralizing antibodies. This finding in human subjects contrasts with results generated by the corresponding regimens in animal models [23, 26] . However, given the size and nature of the clinical trials, along with the resultant wide confidence intervals around the point estimates for ELISpot response frequencies, we cannot confidently exclude the possibility that meaningful differences among the tested vaccine regimens do indeed exist.
Adjuvant effects on immunogenicity may differ based on the specific adjuvant and vaccine being tested, the dosing schedule, and the immune response being measured. The 2 adjuvants used in these studies (AlPO 4 and CRL1005) provided no evident immunological benefit over the DNA vaccine without an Pooling study arms when biologically, methodologically, and statistically appropriate to increase sample size may provide enhanced analytical power, but such analyses may still suffer from type 2 error. The groups receiving the DNA vaccine with either of the 2 adjuvants responded similarly to the group receiving the DNA vaccine without an adjuvant. Consequently, the DNA groups were combined regardless of adjuvant for the formal analysis. It nonetheless remains possible that small effects in opposite directions from a common control might cancel each other in the composite data. As a plausible illustration with regard to the DNA vaccine, responses with the AlPO 4 adjuvant were the highest and responses with the CRL1005 adjuvant were the lowest. Although the differences were not significantly different, numerically higher ELISpot response frequencies were generated by the DNA/Ad5 regimens when the CRL1005 adjuvant arm was excluded than by the Ad5/Ad5 regimen. Even if these small quantitative differences are real, their clinical relevance can be questioned. It remains possible that DNA priming under some circumstances may provide a marginally beneficial strategy to circumvent preexisting or vaccine-induced immunity to an Ad5 vector.
The specific immunogens included in a vaccine and the predominant cell type invoked by the vaccine-adjuvant combination may be critical determinants of the protective efficacy of a CMI-inducing HIV vaccine [37] [38] [39] [40] . Our analysis concentrated on unfractionated ELISpot responses to Gag. Inclusion of env in a vaccine could alter its immunogenicity. Potential qualitative differences in the T cell responses elicited by different vaccine regimens may prove more critical than small quantitative differences in ELISpot responses between the DNA/Ad5 and Ad5/Ad5 regimens. The ELISpot assay exhibits the greatest sensitivity in detecting vaccine responses, whereas the less sensitive intracellular cytokine flow cytometry provides supplemental information on the phenotype of the responding T cells [41] . Our data suggest that the cellular response to the DNA/Ad5 regimen may be broader than the response to DNA/ DNA or Ad5/Ad5 regimens, but whether a broader response translates into better protection remains an unsettled question in human subjects. The effect of a prophylactic DNA/ Ad5 prime-boost vaccine strategy on the HIV set point in uninfected volunteers who acquire infection after vaccination is currently under investigation [42] .
The relevance of nonhuman primate models for evaluation of HIV vaccines has been questioned [43] . Our results in humans are at odds with earlier findings in monkeys regarding the relative merits of a DNA/Ad5 versus an Ad5/Ad5 strategy and the advantages of using adjuvants with the DNA vaccine [23, 26] . An Ad5 vaccine regimen could induce a dominant CD8 + T cell response in rhesus monkeys [23] . Complementary experiments had indicated that Ad5 immunity would mitigate but not abolish the response. Boosting with the Ad5 vaccine after priming with a CRL1005-adjuvanted DNA vaccine produced higher ELISpot responses than Ad5/Ad5 vaccination in monkeys. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with a DNA/Ad5 vaccine regimen was then demonstrated [26] . In contrast, data from the human trials failed to establish any clear-cut quantitative advantage for DNA priming or the use of the CRL1005 adjuvant in overcoming high baseline immunity to Ad5. Definitive conclusions about the relative merits of DNA/Ad5 and Ad5/Ad5 vaccine regimens for protection against HIV and other intracellular pathogens cannot be drawn from our analysis, especially for populations with widespread Ad5 immunity. Our data suggest that DNA priming did little to augment unfractionated IFN-g ELISpot responses to the Ad5 vaccine, even when preimmunization antibody titers to Ad5 were high. A 4-dose immunization series with 2 different vaccines, as used in the DNA/Ad5 strategy studied here, would be logistically more difficult to implement than simpler schedules. If boosting with the last Ad5 vaccine dose were required for an efficacious and durable immune response, the sequential DNA/Ad5 approach could prove counterproductive under circumstances in which the entire vaccine series might not be routinely completed. Other permutations of DNA/Ad5 combination regimens were not studied. Because DNA vaccines induce an immune response that is functionally different from (and perhaps complementary to) that elicited by Ad5-vectored vaccines [37] , DNA/Ad5 prime-boost regimens could potentially offer theoretical advantages over either vaccine alone that were not evident in the unfractionated IFN-g ELISpot responses. Whether the qualitative attributes of a DNA/Ad5 prime-boost regimen will translate into an effective vaccine program has yet to be established.
